RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

<<if ampakines have not caused sleep disturbance in the trials so far. >>

In the ADHD trial, 34% of patients at the high dose had insomnia, compared to 13% of patients on placebo. So CX717 does appear to have some potential to disrupt sleep, at least at higher doses--not surprising in that one of the putative indications was to improve wakefulness and alertness in sleep deprivation (not that the poorly executed, DARPA designed study established that, but I think the evidence is that CX717 can have a waking effect). Which is why I refer to the dosing window as the necessary 'sweet spot.'

NeuroInvestment